id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
ajlm-708	Zhou, Zhiyong; Tang, Kevin; Zhang, Guoqing; Wadonda-Kabondo, Nellie; Moyo, Kundai; Rowe, Lori A.; DeVos, Joshua R.; Wagar, Nick; Zheng, Du-Ping; Guo, Hongxiong; Nkengasong, John; Frace, Mike; Sammons, Scott; Yang, Chunfu	Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy	2018		.htm	text/html	6560	352	51	TABLE 2: Number of drug resistance mutations detected by two sequencing methods against PIs, NRTIs and NNRTIs from plasma specimens collected from patients before ART initiation and at virologic failure† Prevalence of minority drug resistance mutations in patients experiencing virologic failure after antiretroviral therapy Overall, minority DRMs were detected by deep sequencing in 90.5% (19/21) of the patients failing ART. Abstract Background: Minority drug resistance mutations (DRMs) that are often missed by Sanger sequencing are clinically significant, as they can cause virologic failure in individuals treated with antiretroviral therapy (ART) drugs.	cache/ajlm-708.htm	txt/ajlm-708.txt